Fatigue and depression in multiple sclerosis: pharmacological and non-pharmacological interventions

Acta Neurologica Scandinavica

Volumn 134, Issue , 2016, Pages 47-54

  Brenner, P ^a   Piehl, F ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

cognitive symptoms; depression; fatigue; multiple sclerosis; treatment

Indexed keywords

ANTIDEPRESSANT AGENT;

ALERTNESS; ANXIETY DISORDER; COGNITIVE DEFECT; DEPRESSION; DRUG EFFICACY; EXERCISE; FATIGUE; HUMAN; MULTIPLE SCLEROSIS; OFF LABEL DRUG USE; PALLIATIVE THERAPY; PRACTICE GUIDELINE; PSYCHOTHERAPY; REVIEW;

EID: 84984833776     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/ane.12648     Document Type: Review

References (129)

1. Atlas of MS 2013: Mapping Multiple Sclerosis Around the World. Multiple Sclerosis International Federation, 2013.
2. Brain health: time matters in multiple sclerosis. The MS Brain Health initiative, 2015. Accessed April 14th, 2016. http://www.msbrainhealth.org/report
3. Tinghog P, Hillert J, Kjeldgard L, Wiberg M, Glaser A, Alexanderson K. High prevalence of sickness absence and disability pension among multiple sclerosis patients: a nationwide population-based study. Mult Scler. 2013;19:1923–1930.
4. Krause I, Kern S, Horntrich A, Ziemssen T. Employment status in multiple sclerosis: impact of disease-specific and non-disease-specific factors. Mult Scler. 2013;19:1792–1799.
5. Patti F, Pozzilli C, Montanari E, et al. Effects of education level and employment status on HRQoL in early relapsing-remitting multiple sclerosis. Mult Scler. 2007;13:783–791.
6. Jones KH, Ford DV, Jones PA, et al. How people with multiple sclerosis rate their quality of life: an EQ-5D survey via the UK MS register. PLoS One. 2013;8:e65640.
7. Pack TG, Szirony GM, Kushner JD, Bellaw JR. Quality of life and employment in persons with multiple sclerosis. Work. 2014;49:281–287.
8. Charcot J, Gazette HM. Histologie de le sclérose en plaques. pital Paris 557558 1868; 141 SRC - Google Scholar: 554–555.
9. Brenner P, Alexanderson K, Bjorkenstam C, et al. Psychiatric diagnoses, medication and risk for disability pension in multiple sclerosis patients; a population-based register study. PLoS One. 2014;9:e104165.
10. Marrie RA, Reingold S, Cohen J, et al. The incidence and prevalence of psychiatric disorders in multiple sclerosis: a systematic review. Mult Scler. 2015;21:305–317.
11. Bamer AM, Johnson KL, Amtmann D, Kraft GH. Prevalence of sleep problems in individuals with multiple sclerosis. Mult Scler. 2008;14:1127–1130.
12. Glad SB, Nyland H, Aarseth JH, Riise T, Myhr KM. How long can you keep working with benign multiple sclerosis? J Neurol Neurosurg Psychiatry. 2011;82:78–82.
13. van der Hiele K, Middelkoop HA, Ruimschotel R, Kamminga NG, Visser LH. A pilot study on factors involved with work participation in the early stages of multiple sclerosis. PLoS One. 2014;9:e105673.
14. Association AP. The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition.: DSM 5, 2013.
15. Patten SB, Berzins S, Metz LM. Challenges in screening for depression in multiple sclerosis. Mult Scler. 2010;16:1406–1411.
16. Fruehwald S, Loeffler-Stastka H, Eher R, Saletu B, Baumhackl U. Depression and quality of life in multiple sclerosis. Acta Neurol Scand. 2001;104:257–261.
17. Janssens AC, van Doorn PA, de Boer JB, et al. Anxiety and depression influence the relation between disability status and quality of life in multiple sclerosis. Mult Scler. 2003;9:397–403.
18. Marrie RA, Elliott L, Marriott J, Cossoy M, Tennakoon A, Yu N. Comorbidity increases the risk of hospitalizations in multiple sclerosis. Neurology. 2015;84:350–358.
19. Tarrants M, Oleen-Burkey M, Castelli-Haley J, Lage MJ. The impact of comorbid depression on adherence to therapy for multiple sclerosis. Mult Scler Int. 2011;2011:271321.
20. Zabad RK, Patten SB, Metz LM. The association of depression with disease course in multiple sclerosis. Neurology. 2005;64:359–360.
21. Moore P, Hirst C, Harding KE, Clarkson H, Pickersgill TP, Robertson NP. Multiple sclerosis relapses and depression. J Psychosom Res. 2012;73:272–276.
22. Patten SB, Metz LM. Hopelessness ratings in relapsing-remitting and secondary progressive multiple sclerosis. Int J Psychiatry Med. 2002;32:155–165.
23. Feinstein A, Magalhaes S, Richard JF, Audet B, Moore C. The link between multiple sclerosis and depression. Nat Rev Neurol. 2014;10:507–517.
24. Arnett PA, Barwick FH, Beeney JE. Depression in multiple sclerosis: review and theoretical proposal. J Int Neuropsychol Soc. 2008;14:691–724.
25. Lynch SG, Kroencke DC, Denney DR. The relationship between disability and depression in multiple sclerosis: the role of uncertainty, coping, and hope. Mult Scler. 2001;7:411–416.
26. Mohr DC, Boudewyn AC, Goodkin DE, Bostrom A, Epstein L. Comparative outcomes for individual cognitive-behavior therapy, supportive-expressive group psychotherapy, and sertraline for the treatment of depression in multiple sclerosis. J Consult Clin Psychol. 2001;69:942–949.
27. Hasselmann H, Bellmann-Strobl J, Ricken R, et al. Characterizing the phenotype of multiple sclerosis-associated depression in comparison with idiopathic major depression. Mult Scler. 2016; doi: 10.1177/1352458515622826. [Epub ahead of print].
28. Feinstein A, Roy P, Lobaugh N, Feinstein K, O'Connor P, Black S. Structural brain abnormalities in multiple sclerosis patients with major depression. Neurology. 2004;62:586–590.
29. Kiy G, Lehmann P, Hahn HK, Eling P, Kastrup A, Hildebrandt H. Decreased hippocampal volume, indirectly measured, is associated with depressive symptoms and consolidation deficits in multiple sclerosis. Mult Scler. 2011;17:1088–1097.
30. Gold SM, Kern KC, O'Connor MF, et al. Smaller cornu ammonis 2-3/dentate gyrus volumes and elevated cortisol in multiple sclerosis patients with depressive symptoms. Biol Psychiatry. 2010;68:553–559.
31. Feinstein A, O'Connor P, Akbar N, Moradzadeh L, Scott CJ, Lobaugh NJ. Diffusion tensor imaging abnormalities in depressed multiple sclerosis patients. Mult Scler. 2010;16:189–196.
32. Riccelli R, Passamonti L, Cerasa A, et al. Individual differences in depression are associated with abnormal function of the limbic system in multiple sclerosis patients. Mult Scler. 2016;22:1094–1105.
33. Lalmohamed A, Bazelier MT, van Staa TP, et al. Causes of death in patients with multiple sclerosis and matched referent subjects: a population-based cohort study. Eur J Neurol. 2012;19:1007–1014.
34. Kahana E, Leibowitz U, Alter M. Cerebral multiple sclerosis. Neurology. 1971;21:1179–1185.
35. Fredrikson S, Cheng Q, Jiang GX, Wasserman D. Elevated suicide risk among patients with multiple sclerosis in Sweden. Neuroepidemiology. 2003;22:146–152.
36. Bronnum-Hansen H, Stenager E, Nylev Stenager E, Koch-Henriksen N. Suicide among Danes with multiple sclerosis. J Neurol Neurosurg Psychiatry. 2005;76:1457–1459.
37. Brenner P, Burkill S, Jokinen J, Bahmanyar S, Montgomery S. Multiple sclerosis and risk of attempted and completed suicide – a cohort study. Eur J Neurol. 2016;23:1329–1336.
38. Dickstein LP, Viguera AC, Nowacki AS, et al. Thoughts of death and self-harm in patients with epilepsy or multiple sclerosis in a tertiary care center. Psychosomatics. 2015;56:44–51.
39. Flood S, Foley FW, Zemon V, Picone M, Bongardino M, Quinn H. Predictors of changes in suicidality in multiple sclerosis over time. Disabil Rehabil. 2014;36:844–847.
40. Viner R, Patten SB, Berzins S, Bulloch AG, Fiest KM. Prevalence and risk factors for suicidal ideation in a multiple sclerosis population. J Psychosom Res. 2014;76:312–316.
41. Mohr DC, Hart SL, Julian L, Tasch ES. Screening for depression among patients with multiple sclerosis: two questions may be enough. Mult Scler. 2007;13:215–219.
42. Patten SB, Burton JM, Fiest KM, et al. Validity of four screening scales for major depression in MS. Mult Scler. 2015;21:1064–1071.
43. Quaranta D, Marra C, Zinno M, et al. Presentation and validation of the multiple sclerosis depression rating scale: a test specifically devised to investigate affective disorders in multiple sclerosis patients. Clin Neuropsychol. 2012;26:571–587.
44. Fischer A, Fischer M, Nicholls RA, et al. Diagnostic accuracy for major depression in multiple sclerosis using self-report questionnaires. Brain Behav. 2015;5:e00365.
45. Feinstein A, O'Connor P, Gray T, Feinstein K. The effects of anxiety on psychiatric morbidity in patients with multiple sclerosis. Mult Scler. 1999;5:323–326.
46. Stenager EN, Stenager E, Koch-Henriksen N, et al. Suicide and multiple sclerosis: an epidemiological investigation. J Neurol Neurosurg Psychiatry. 1992;55:542–545.
47. Korostil M, Feinstein A. Anxiety disorders and their clinical correlates in multiple sclerosis patients. Mult Scler. 2007;13:67–72.
48. Koch MW, Glazenborg A, Uyttenboogaart M, Mostert J, de Keyser J. Pharmacologic treatment of depression in multiple sclerosis. Cochrane Database Syst Rev. 2011;CD007295.
49. Ehde DM, Kraft GH, Chwastiak L, et al. Efficacy of paroxetine in treating major depressive disorder in persons with multiple sclerosis. Gen Hosp Psychiatry. 2008;30:40–48.
50. Schiffer RB, Wineman NM. Antidepressant pharmacotherapy of depression associated with multiple sclerosis. Am J Psychiatry. 1990;147:1493–1497.
51. Fiest KM, Walker JR, Bernstein CN, et al. Systematic review and meta-analysis of interventions for depression and anxiety in persons with multiple sclerosis. Mult Scler Relat Disord. 2016;5:12–26.
52. National Institute for Health and Clinical Excellence. Depression in Adults: Recognition and Management. NICE Guideline (CG90). 2009.
53. Taylor D, Paton C, Kapur S, Taylor D, South London and Maudsley NHS Trust. The Maudsley Prescribing Guidelines in Psychiatry. Chichester: John Wiley & Sons; 2012.
54. Lincoln NB, Yuill F, Holmes J, et al. Evaluation of an adjustment group for people with multiple sclerosis and low mood: a randomized controlled trial. Mult Scler. 2011;17:1250–1257.
55. Fischer A, Schroder J, Vettorazzi E, et al. An online programme to reduce depression in patients with multiple sclerosis: a randomised controlled trial. Lancet Psychiatry. 2015;2:217–223.
56. Mohr DC, Cox D, Epstein L, Boudewyn A. Teaching patients to self-inject: pilot study of a treatment for injection anxiety and phobia in multiple sclerosis patients prescribed injectable medications. J Behav Ther Exp Psychiatry. 2002;33:39–47.
57. National Institute for Health and Clinical Excellence. Generalised Anxiety Disorder and Panic Disorder in Adults: Management. NICE Guideline (CG113). 2011.
58. Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol. 2014;28:403–439.
59. Krupp L. Fatigue is intrinsic to multiple sclerosis (MS) and is the most commonly reported symptom of the disease. Mult Scler. 2006;12:367–368.
60. Lerdal A, Celius EG, Krupp L, Dahl AA. A prospective study of patterns of fatigue in multiple sclerosis. Eur J Neurol. 2007;14:1338–1343.
61. Shah A. Fatigue in multiple sclerosis. Phys Med Rehabil Clin N Am. 2009;20:363–372.
62. Guidelines MSCfCP. Fatigue and Multiple Sclerosis: Evidence-based Management Strategies for Fatigue in Multiple Sclerosis: Clinical Practice Guidelines: The Council. Washington DC: Paralyzed Veterans of America; 1998.
63. Mills RJ, Young CA. A medical definition of fatigue in multiple sclerosis. QJM. 2008;101:49–60.
64. Patrick E, Christodoulou C, Krupp LB, New YORK, State MSC. Longitudinal correlates of fatigue in multiple sclerosis. Mult Scler. 2009;15:258–261.
65. Mills RJ, Young CA, Pallant JF, Tennant A. Development of a patient reported outcome scale for fatigue in multiple sclerosis: The Neurological Fatigue Index (NFI-MS). Health Qual Life Outcomes. 2010;8:22.
66. Bakshi R, Miletich RS, Henschel K, et al. Fatigue in multiple sclerosis: cross-sectional correlation with brain MRI findings in 71 patients. Neurology. 1999;53:1151–1153.
67. Niepel G, Tench CHR, Morgan PS, Evangelou N, Auer DP, Constantinescu CS. Deep gray matter and fatigue in MS: a T1 relaxation time study. J Neurol. 2006;253:896–902.
68. Tedeschi G, Dinacci D, Lavorgna L, et al. Correlation between fatigue and brain atrophy and lesion load in multiple sclerosis patients independent of disability. J Neurol Sci. 2007;263:15–19.
69. Yaldizli O, Penner IK, Frontzek K, et al. The relationship between total and regional corpus callosum atrophy, cognitive impairment and fatigue in multiple sclerosis patients. Mult Scler. 2014;20:356–364.
70. Kroencke DC, Lynch SG, Denney DR. Fatigue in multiple sclerosis: relationship to depression, disability, and disease pattern. Mult Scler. 2000;6:131–136.
71. Bakshi R, Shaikh ZA, Miletich RS, et al. Fatigue in multiple sclerosis and its relationship to depression and neurologic disability. Mult Scler. 2000;6:181–185.
72. Krupp LB, Serafin DJ, Christodoulou C. Multiple sclerosis-associated fatigue. Expert Rev Neurother. 2010;10:1437–1447.
73. Brown RF, Valpiani EM, Tennant CC, et al. Longitudinal assessment of anxiety, depression, and fatigue in people with multiple sclerosis. Psychol Psychother. 2009;82:41–56.
74. Fisk JD, Pontefract A, Ritvo PG, Archibald CJ, Murray TJ. The impact of fatigue on patients with multiple sclerosis. Can J Neurol Sci. 1994;21:9–14.
75. Schwartz CE, Coulthard-Morris L, Zeng Q. Psychosocial correlates of fatigue in multiple sclerosis. Arch Phys Med Rehabil. 1996;77:165–170.
76. Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology. 1991;41:685–691.
77. McIntosh-Michaelis SA, Roberts MH, Wilkinson SM, et al. The prevalence of cognitive impairment in a community survey of multiple sclerosis. Br J Clin Psychol. 1991;30(Pt 4):333–348.
78. Rao SM, Leo GJ, St Aubin-Faubert P. On the nature of memory disturbance in multiple sclerosis. J Clin Exp Neuropsychol. 1989;11:699–712.
79. Feinstein A. The Clinical Neuropsychiatry of Multiple Sclerosis. New York: Cambridge University Press; 2007.
80. Thornton AE, Raz N. Memory impairment in multiple sclerosis: a quantitative review. Neuropsychology. 1997;11:357–366.
81. Arnett PA, Higginson CI, Voss WD, Bender WI, Wurst JM, Tippin JM. Depression in multiple sclerosis: relationship to working memory capacity. Neuropsychology. 1999;13:546–556.
82. Nunnari D, de Cola MC, D'Aleo G, et al. Impact of depression, fatigue, and global measure of cortical volume on cognitive impairment in multiple sclerosis. BioMed Res Int. 2015;2015:519785.
83. Sundgren M, Maurex L, Wahlin A, Piehl F, Brismar T. Cognitive impairment has a strong relation to nonsomatic symptoms of depression in relapsing-remitting multiple sclerosis. Arch Clin Neuropsychol. 2013;28:144–155.
84. Bol Y, Duits AA, Hupperts RM, Vlaeyen JW, Verhey FR. The psychology of fatigue in patients with multiple sclerosis: a review. J Psychosom Res. 2009;66:3–11.
85. Morrow SA, Weinstock-Guttman B, Munschauer FE, Hojnacki D, Benedict RH. Subjective fatigue is not associated with cognitive impairment in multiple sclerosis: cross-sectional and longitudinal analysis. Mult Scler. 2009;15:998–1005.
86. Hanken K, Eling P, Hildebrandt H. Is there a cognitive signature for MS-related fatigue? Mult Scler. 2015;21:376–381.
87. Feinstein A. Is there a cognitive signature for multiple sclerosis-related fatigue? Mult Scler. 2015;21:353–354.
88. Amato MP, Zipoli V, Goretti B, et al. Benign multiple sclerosis: cognitive, psychological and social aspects in a clinical cohort. J Neurol. 2006;253:1054–1059.
89. Amato MP, Ponziani G, Siracusa G, Sorbi S. Cognitive dysfunction in early-onset multiple sclerosis: a reappraisal after 10 years. Arch Neurol. 2001;58:1602–1606.
90. Strober LB, Rao SM, Lee JC, Fischer E, Rudick R. Cognitive impairment in multiple sclerosis: an 18 year follow-up study. Mult Scler Relat Disord. 2014;3:473–481.
91. Nocentini U, Pasqualetti P, Bonavita S, et al. Cognitive dysfunction in patients with relapsing-remitting multiple sclerosis. Mult Scler. 2006;12:77–87.
92. Smith A. Symbol Digits Modalities Test (SDMT) Manual, Revised. Los Angeles: Western Publishing Services; 1982.
93. Nocentini U, Caltagirone C, Tedeschi G. Neuropsychiatric Dysfunction in Multiple Sclerosis. Milan: Springer; 2012.
94. Deluca J, Barbieri-Berger S, Johnson SK. The nature of memory impairments in multiple sclerosis: acquisition versus retrieval. J Clin Exp Neuropsychol. 1994;16:183–189.
95. Deluca J, Gaudino EA, Diamond BJ, Christodoulou C, Engel RA. Acquisition and storage deficits in multiple sclerosis. J Clin Exp Neuropsychol. 1998;20:376–390.
96. Langdon DW, Amato MP, Boringa J, et al. Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS). Mult Scler. 2012;18:891–898.
97. Delis DC. California Verbal Learning Test, Second Edition: CvLT-II; Adult Version; Manual. New York: Pearson; 2000.
98. Benedict RHB, Psychological Assessment Resources I. Brief Visuospatial Memory Test–Revised: Professional Manual. Lutz, FL: PAR; 1997.
99. Heaton RK. Wisconsin Card Sorting Test Manual. Lutz, FL: PAR; 2008.
100. Delis DC, Kaplan E, Kramer JH. D-KEFS. Psychological Corporation; 2001.
101. Birnboim S, Miller A. Cognitive strategies application of multiple sclerosis patients. Mult Scler. 2004;10:67–73.
102. Arnett PA, Rao SM, Bernardin L, Grafman J, Yetkin FZ, Lobeck L. Relationship between frontal lobe lesions and Wisconsin Card Sorting Test performance in patients with multiple sclerosis. Neurology. 1994;44:420–425.
103. Nocentini U, Rossini PM, Carlesimo GA, et al. Patterns of cognitive impairment in secondary progressive stable phase of multiple sclerosis: correlations with MRI findings. Eur Neurol. 2001;45:11–18.
104. Stuss DT, Levine B. Adult clinical neuropsychology: lessons from studies of the frontal lobes. Annu Rev Psychol. 2002;53:401–433.
105. Rao SM, Leo GJ, Haughton VM, St Aubin-Faubert P, Bernardin L. Correlation of magnetic resonance imaging with neuropsychological testing in multiple sclerosis. Neurology. 1989;39:161–166.
106. Lazeron RH, Langdon DW, Filippi M, et al. Neuropsychological impairment in multiple sclerosis patients: the role of (juxta)cortical lesion on FLAIR. Mult Scler. 2000;6:280–285.
107. Benedict RH, Weinstock-Guttman B, Fishman I, Sharma J, Tjoa CW, Bakshi R. Prediction of neuropsychological impairment in multiple sclerosis: comparison of conventional magnetic resonance imaging measures of atrophy and lesion burden. Arch Neurol. 2004;61:226–230.
108. Rovaris M, Iannucci G, Falautano M, et al. Cognitive dysfunction in patients with mildly disabling relapsing-remitting multiple sclerosis: an exploratory study with diffusion tensor MR imaging. J Neurol Sci. 2002;195:103–109.
109. Staffen W, Mair A, Zauner H, et al. Cognitive function and fMRI in patients with multiple sclerosis: evidence for compensatory cortical activation during an attention task. Brain. 2002;125:1275–1282.
110. Penner IK, Rausch M, Kappos L, Opwis K, Radu EW. Analysis of impairment related functional architecture in MS patients during performance of different attention tasks. J Neurol. 2003;250:461–472.
111. Stankoff B, Waubant E, Confavreux C, et al. Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study. Neurology. 2005;64:1139–1143.
112. Moller F, Poettgen J, Broemel F, Neuhaus A, Daumer M, Heesen C. HAGIL (Hamburg Vigil Study): a randomized placebo-controlled double-blind study with modafinil for treatment of fatigue in patients with multiple sclerosis. Mult Scler. 2011;17:1002–1009.
113. Rammohan KW, Rosenberg JH, Lynn DJ, Blumenfeld AM, Pollak CP, Nagaraja HN. Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study. J Neurol Neurosurg Psychiatry. 2002;72:179–183.
114. Lange R, Volkmer M, Heesen C, Liepert J. Modafinil effects in multiple sclerosis patients with fatigue. J Neurol. 2009;256:645–650.
115. Morrow SA, Smerbeck A, Patrick K, Cookfair D, Weinstock-Guttman B, Benedict RH. Lisdexamfetamine dimesylate improves processing speed and memory in cognitively impaired MS patients: a phase II study. J Neurol. 2013;260:489–497.
116. Pucci E, Branas P, D'Amico R, Giuliani G, Solari A, Taus C. Amantadine for fatigue in multiple sclerosis. Cochrane Database Syst Rev. 2007;CD002818.
117. Ledinek AH, Sajko MC, Rot U. Evaluating the effects of amantadin, modafinil and acetyl-L-carnitine on fatigue in multiple sclerosis – result of a pilot randomized, blind study. Clin Neurol Neurosurg. 2013;115(Suppl 1):S86–S89.
118. Shaygannejad V, Janghorbani M, Ashtari F, Zakeri H. Comparison of the effect of aspirin and amantadine for the treatment of fatigue in multiple sclerosis: a randomized, blinded, crossover study. Neurol Res. 2012;34:854–858.
119. Kos D, Duportail M, D'Hooghe M, Nagels G, Kerckhofs E. Multidisciplinary fatigue management programme in multiple sclerosis: a randomized clinical trial. Mult Scler. 2007;13:996–1003.
120. Finlayson M, Preissner K, Cho C, Plow M. Randomized trial of a teleconference-delivered fatigue management program for people with multiple sclerosis. Mult Scler. 2011;17:1130–1140.
121. Garcia Jalon EG, Lennon S, Peoples L, Murphy S, Lowe-Strong A. Energy conservation for fatigue management in multiple sclerosis: a pilot randomized controlled trial. Clin Rehabil. 2013;27:63–74.
122. Briken S, Gold SM, Patra S, et al. Effects of exercise on fitness and cognition in progressive MS: a randomized, controlled pilot trial. Mult Scler. 2014;20:382–390.
123. Dodd KJ, Taylor NF, Shields N, Prasad D, McDonald E, Gillon A. Progressive resistance training did not improve walking but can improve muscle performance, quality of life and fatigue in adults with multiple sclerosis: a randomized controlled trial. Mult Scler. 2011;17:1362–1374.
124. Bogosian A, Chadwick P, Windgassen S, et al. Distress improves after mindfulness training for progressive MS: a pilot randomised trial. Mult Scler. 2015;21:1184–1194.
125. Oken BS, Kishiyama S, Zajdel D, et al. Randomized controlled trial of yoga and exercise in multiple sclerosis. Neurology. 2004;62:2058–2064.
126. Burschka JM, Keune PM, Oy UH, Oschmann P, Kuhn P. Mindfulness-based interventions in multiple sclerosis: beneficial effects of Tai Chi on balance, coordination, fatigue and depression. BMC Neurol. 2014;14:165.
127. Thomas S, Thomas PW, Kersten P, et al. A pragmatic parallel arm multi-centre randomised controlled trial to assess the effectiveness and cost-effectiveness of a group-based fatigue management programme (FACETS) for people with multiple sclerosis. J Neurol Neurosurg Psychiatry. 2013;84:1092–1099.
128. Asano M, Finlayson ML. Meta-analysis of three different types of fatigue management interventions for people with multiple sclerosis: exercise, education, and medication. Mult Scler Int. 2014;2014:798285.
129. Heine M, van de Port I, Rietberg MB, van Wegen EE, Kwakkel G. Exercise therapy for fatigue in multiple sclerosis. Cochrane Database Syst Rev. 2015;9:CD009956.